Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selma Ugurel

Showing results (131-140 of 265) with videos related to

Pageof 27
Sort By:
Cancer Immunology, Immunotherapy : CII|December 4, 2020
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytesLukas Peiffer, Farnoush Farahpour, Ashwin Sriram, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2013
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsSimone M Goldinger, Lisa Zimmer, Carsten Schulz, et al.
Frontiers in Oncology|September 12, 2022
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion ratesGeorg C Lodde, Melanie Fiedler, Ulf Dittmer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2019
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanomaTheodora Kanaki, Andreas Stang, Ralf Gutzmer, et al.
Plos One|February 22, 2007
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosisSelma Ugurel, Ranjit K Thirumaran, Sandra Bloethner, et al.
Oncogene|December 14, 2020
Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53Kaiji Fan, Ivelina Spassova, Jan Gravemeyer, et al.
Scientific Reports|April 16, 2024
Comparison of visual diagnostic accuracy of dermatologists practicing in Germany in patients with light skin and skin of colorFrederik Krefting, Maurice Moelleken, Stefanie Hölsken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology GroupSelma Ugurel, Dirk Schadendorf, Claudia Pföhler, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2020
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasisEleftheria Chorti, Theodora Kanaki, Lisa Zimmer, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 6, 2022
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaJustin Ferdinandus, Anne Zaremba, Lisa Zimmer, et al.
Pageof 27

Showing results (131-140 of 265) with videos related to

Sort By:
Pageof 27
Cancer Immunology, Immunotherapy : CII|December 4, 2020
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytesLukas Peiffer, Farnoush Farahpour, Ashwin Sriram, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2013
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsSimone M Goldinger, Lisa Zimmer, Carsten Schulz, et al.
Frontiers in Oncology|September 12, 2022
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion ratesGeorg C Lodde, Melanie Fiedler, Ulf Dittmer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2019
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanomaTheodora Kanaki, Andreas Stang, Ralf Gutzmer, et al.
Plos One|February 22, 2007
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosisSelma Ugurel, Ranjit K Thirumaran, Sandra Bloethner, et al.
Oncogene|December 14, 2020
Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53Kaiji Fan, Ivelina Spassova, Jan Gravemeyer, et al.
Scientific Reports|April 16, 2024
Comparison of visual diagnostic accuracy of dermatologists practicing in Germany in patients with light skin and skin of colorFrederik Krefting, Maurice Moelleken, Stefanie Hölsken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology GroupSelma Ugurel, Dirk Schadendorf, Claudia Pföhler, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2020
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasisEleftheria Chorti, Theodora Kanaki, Lisa Zimmer, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 6, 2022
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaJustin Ferdinandus, Anne Zaremba, Lisa Zimmer, et al.
Pageof 27